Mazdutide Shows Significant Weight Loss in Phase 3 Trial
Key Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreKey Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreThe rising obesity epidemic has fueled demand for effective weight loss treatments. While GLP-1 receptor agonists like Ozempic have gained
Read More